ADC Therapeutics
ADCT
51 hedge funds and large institutions have $1.01B invested in ADC Therapeutics in 2020 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 15 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
10% more capital invested
Capital invested by funds: $921M → $1.01B (+$90.8M)
4.4% more ownership
Funds ownership: 36.79% → 41.19% (+4.4%)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
2% less funds holding
Funds holding: 52 → 51 (-1)
63% less call options, than puts
Call options by funds: $227K | Put options by funds: $611K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40.9M |
| 2 |
JP Morgan Chase
New York
|
+$29.4M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$16.5M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$16.2M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$49.6M |
| 2 |
DM
Deerfield Management
New York
|
-$9.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$8.83M |
| 4 |
PI
PEAK6 Investments
Chicago,
Illinois
|
-$6.59M |
| 5 |
IM
Islet Management
New York
|
-$6.2M |
ADCT Hedge Fund Activity: Q4 2020 in Review
51 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q4 2020, worth a combined $1.01B — up 9.9% from $921M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ADCT and 14 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 16 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $40.9M. The largest seller was Magnetar Financial, cutting an estimated $49.6M.
- 51 institutional investors held ADC Therapeutics (ADCT) as of Q4 2020, down from 52 in Q3 2020.
- Funds reported $1.01B of ADC Therapeutics stock for Q4 2020, up 9.9% quarter-over-quarter.
- 14 funds opened new ADC Therapeutics positions in Q4 2020 and 15 closed out, a net change of -1 holder.
- The largest ADC Therapeutics buyer in Q4 2020 was T. Rowe Price Associates, an estimated $40.9M added.
- The largest ADC Therapeutics seller in Q4 2020 was Magnetar Financial, an estimated $49.6M sold.
Based on aggregated 13F filings for Q4 2020.